目的 比較Beers標(biāo)準(zhǔn)（2019版）、老年人不適當(dāng)處方篩查工具（STOPP）/老年人處方遺漏篩查工具（START）標(biāo)準(zhǔn)（2014版）及中國老年人潛在不適當(dāng)用藥判斷標(biāo)準(zhǔn)（中國PIM標(biāo)準(zhǔn)）對(duì)河南省人民醫(yī)院神經(jīng)內(nèi)科老年多重用藥患者不適當(dāng)用藥的異同。方法 回顧性分析2019年河南省人民醫(yī)院神經(jīng)內(nèi)科住院的老年患者醫(yī)囑，以3種標(biāo)準(zhǔn)為評(píng)價(jià)依據(jù)進(jìn)行對(duì)比分析。結(jié)果 納入患者223例，依照中國PIM標(biāo)準(zhǔn)，審查出潛在不適當(dāng)用藥170例，其中高風(fēng)險(xiǎn)40例，低風(fēng)險(xiǎn)126例，疾病狀態(tài)下潛在不適當(dāng)用藥4例；依照Beers標(biāo)準(zhǔn)，共審查出潛在不適當(dāng)用藥228例，其中避免使用的潛在不適當(dāng)用藥89例，與疾病狀態(tài)相關(guān)的不適當(dāng)用藥10例，謹(jǐn)慎使用藥物113例，非抗感染藥物間相互作用15例及腎功不全使用非抗感染藥物的警示病例1例；依據(jù)STOPP/START標(biāo)準(zhǔn)審查出潛在不適當(dāng)用藥109例，處方遺漏70例。結(jié)論 各國標(biāo)準(zhǔn)均存在一定的優(yōu)勢(shì)和局限性，建議中國標(biāo)準(zhǔn)取長補(bǔ)短，在完善當(dāng)前內(nèi)容的同時(shí)，增加相互作用、聯(lián)合用藥等內(nèi)容。

Objective The Beers criteria (2019 Edition), STOPP/START criteria (2014 Edition) and Chinese elderly potential inappropriate drug use criteria (PIM criteria) were compared for inappropriate drug use among elderly patients in department of Neurology, Henan Provincial People's Hospital.Methods The medical orders of elderly patients hospitalized in the Department of Neurology of Henan Provincial People's Hospital in 2019 were retrospectively analyzed, and the three criteria were used as evaluation basis for comparative analysis.Results A total of 223 patients were included, including 170 cases of potential inappropriate drug use according to Chinese criteria, including 40 cases of high risk, 126 cases of low risk, and 4 cases of potential inappropriate drug use under disease status. A total of 228 cases of potential inappropriate drug use were identified according to Beers criteria, including 89 cases of potential inappropriate drug use avoided, 10 cases of inappropriate drug use related to disease status, 113 cases of cautious drug use, 15 cases of noninfective drug interaction, and 1 case of noninfective drug use warning for renal insufficiency. According to STOPP/START criteria, 109 cases of potential inappropriate drug use and 70 cases of prescription omission were examined.Conclusion There are certain advantages and limitations in the standards of various countries. It is suggested to learn from each other's strengths and complement each other's weaknesses. While improving the current content, the contents of interaction and drug combination should be added.

R971

河南省科技廳科技發(fā)展計(jì)劃項(xiàng)目（202102310656）